ClinicalTrials.gg
RecruitingNCT07388173AFIRIUpdated May 8, 2026

Functional Impact of Acute Respiratory Viral Infections in Older Adults

An observational study in Respiratory Infections in Old Age, sponsored by University Hospital, Grenoble. Recruiting at 24 sites in 5 countries. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by University Hospital, Grenoble · Observational

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
1,600
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 34 studies in Respiratory Tract Infections with a site in Italy — 11 open to participants now, 13 under way, 2 of them phase 3. Respiratory Tract Infections · Italy.

Planned enrollment
3rd of 10
1,600 · median 700
Started
2026
with 1 other
Observational
10 of 34
5 open now
Primary completion
2028-01
later than 8 of 12 live
Registered
32nd of 34
by date
Lead sponsor
2 of 34
University Hospital, Grenoble

Among the 34 studies in Respiratory Tract Infections with a site in Italy, this one is the 3rd largest by planned enrollment of the 10 observational ones that give a count, is one of 2 that started in 2026, is one of 10 observational ones, reaches primary completion later than 8 of the 12 other live ones, and was the 32nd registered.

Respiratory Tract Infections

753 studies on the registry are indexed under Respiratory Tract Infections; 112 are open to participants now.

Browse Respiratory Tract Infections studies →

Open to participants now

11 of the 34 studies in Respiratory Tract Infections with a site in Italy are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 73 Respiratory Tract Infections studies recruiting now, 33 (45%) set no upper age limit and 32 (44%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 60 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Respiratory Tract Infections with a site in Italy, or all of them as a file.
02

Study summary

The prevention of infectious diseases in older adults remains a major public health challenge, as acute respiratory infections are a leading cause of hospitalisation, mortality, and functional decline worldwide. Immunosenescence and environmental exposures increase susceptibility to infection and reduce vaccine effectiveness in this population. Respiratory viruses, including influenza, SARS-CoV-2, respiratory syncytial virus, and human metapneumovirus, account for a substantial share of this burden, much of which is vaccine-preventable. However, their impact on functional decline and recovery in older adults remains insufficiently characterized. This international study aims to assess the effect of hospitalization for major respiratory viral infections on loss of autonomy in individuals aged 60 years and older, to inform targeted prevention and vaccination strategies.

Read the detailed description

The prevention of infectious diseases in older adults represents a major public health challenge due to their substantial impact on morbidity, mortality, and loss of functional capacity. Acute respiratory infections are among the leading causes of hospitalization and death in this population worldwide.

Ageing is associated with a progressive decline in immune function, resulting in increased susceptibility to infections and reduced vaccine effectiveness. In addition, environmental factors such as residence in collective living settings and repeated exposure to healthcare environments further increase the risk of exposure to and transmission of infectious agents.

The pathogens most frequently involved include respiratory viruses namely influenza, SARS-CoV-2, respiratory syncytial virus, and human metapneumovirus as well as bacterial pathogens, particularly Streptococcus pneumoniae, and certain fungal agents. A substantial proportion of these infections are potentially preventable through vaccination.

Despite advances generated by the European IMI VITAL project and the AEQUI case-control study, data remain limited regarding the functional consequences of acute respiratory infections in older adults, particularly their impact on dependency, frailty, and post-infectious recovery.

This international study aims to address these knowledge gaps by evaluating the impact of hospitalizations related to influenza, SARS-CoV-2, respiratory syncytial virus, and human metapneumovirus on loss of autonomy in individuals aged 60 years and older. The findings are expected to strengthen the scientific evidence base needed to inform targeted vaccination and prevention strategies, ultimately contributing to healthier ageing.

03

Conditions studied

  • Respiratory Infections in Old Age

Keywords

  • functional dependency
  • respiratory infection
  • elderly people
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

The study population will include participants aged 60 years or older who are hospitalized with a serious acute respiratory infection in the departments of infectious diseases, geriatrics, internal medicine, pulmonology, or emergency medicine. Recruitment will be conducted by investigator physicians in each participating department. Potentially eligible participants will be identified by daily screening of admission records and results from standard of care respiratory samples.

Each country will aim to recruit approximately 320 participants - 80 with each pathogen of interest. Efforts will be made to secure an equal distribution of participants aged 60-75 and >75 years age.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects aged 60 years or older
  • Hospitalized in a study center (emergency department, infectious disease, internal medicine or geriatric hospital wards…) for acute respiratory infection (refer to table 1 below for definition).
  • Confirmed positive PCR test for influenza, SARS-CoV-2, RSV, or human metapneumovirus (hMPV). Participants with co-infections with other viral or bacterial agents can be included.

Exclusion criteria

Exclusion Criteria:

  • Participants with conditions significantly impacting short-term functional status, such as severe disability (ADL score ≤2 or Clinical Frailty Scale ≥7), terminal illness, palliative care needs, or inability to comprehend and complete study questionnaires due to severe stroke sequelae, complete sensory loss, advanced dementia, or similar impairments.
  • Participants that refuse or are unable to answer the 3- and 6-months follow-up phone call assessments
  • Positive laboratory test for single (mono-infection) virus other than influenza, SARS-CoV-2, RSV, or human metapneumovirus (HMPV)
  • Participant in exclusion period for another study using an / unapproved medicinal product.
  • Participant referred to in articles L1121-5 to L1121-8 of the CSP (corresponding to all protected persons : pregnant woman, parturient, breastfeeding mother, person deprived of liberty by judicial or administrative decision, persons undergoing psychiatric care under articles L.3212-1 and L.3213-1 who do not fall under article L.1121-8, persons admitted to a healthcare or social institution for purposes other than research, minors, person under legal protection or unable to express consent).
  • Individuals opposed to participating in the research
  • Staff members with a hierarchical relationship to the principal investigator
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
1,600 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Evolution of Functional Dependency assessed by Activities of Daily Living (ADL) Score

    Change in functional performance measured using the Activities of Daily Living (ADL) scale. The ADL score ranges from 0 to 6, where higher scores indicate better functional independence The ADL score ranges from 0 to 6, where higher scores indicate better functional independence.

    Time frame: Baseline, at hospital discharge, 3 months after discharge, and 6 months after discharge.

  2. Evolution of Functional Dependency assessed by Instrumental Activities of Daily Living (IADL) Score

    Change in functional performance measured using the Instrumental Activities of Daily Living (IADL) scale. The IADL score ranges from 0 to 8, where higher scores indicate better functional independence.

    Time frame: Baseline, Day 7, 3 months after discharge, and 6 months after discharge.

Secondary outcomes

  1. Functional Status depending on Viral Etiology Assessed by Activities of Daily Living (ADL) Score

    Change in functional status measured using the Activities of Daily Living (ADL) scale. The ADL score ranges from 0 to 6, where higher scores indicate better functional independence. Changes in score will be assessed between baseline, hospital discharge, 3 months, and 6 months, and stratified by viral etiology (SARS-CoV-2, influenza, respiratory syncytial virus (RSV), and human metapneumovirus (hMPV)).

    Time frame: Baseline, Day 7, 3 months after discharge, and 6 months after discharge.

  2. Functional Status depending on Viral Etiology Assessed by Instrumental Activities of Daily Living (IADL) Score

    Change in functional status measured using the Instrumental Activities of Daily Living (IADL) scale. The IADL score ranges from 0 to 8, where higher scores indicate better functional independence. Changes in score will be assessed between baseline, hospital discharge, 3 months, and 6 months, and stratified by viral etiology (SARS-CoV-2, influenza, respiratory syncytial virus (RSV), and human metapneumovirus (hMPV)).

    Time frame: Baseline, Day 7, 3 months after discharge, and 6 months after discharge.

  3. Medical Complications during and after hospitalization

    Occurrence of medical complications during hospitalization and up to 6 months after discharge, including new diagnoses identified during follow-up.

    Time frame: From hospital admission to 6 months after discharge.

  4. Health Care Resource Utilization (HCRU)

    Health care resource utilization, including hospital length of stay, intensive care unit (ICU) admission during index hospitalization, and hospital readmissions occurring between discharge and 6 months.

    Time frame: From hospital admission to 6 months after discharge.

  5. Length of Hospital Stay

    Duration of the index hospitalization, measured in days, calculated from hospital admission (Day 1) to hospital discharge.

    Time frame: 3 months after discharge

  6. Intensive Care Unit (ICU) Admission

    Proportion of participants admitted to an intensive care unit during the index hospitalization.

    Time frame: 3 months after hospital discharge.

  7. Hospital Readmissions After Discharge

    Occurrence of hospital readmissions between discharge and 6 months after discharge.

    Time frame: From at hospital discharge to 6 months after discharge.

  8. New Medications Initiated

    Initiation of new drug treatments during hospitalization or within 6 months after discharge.

    Time frame: From hospital admission to 6 months after discharge.

  9. Discharge Location after Hospitalization

    Location at hospital discharge (e.g., home, rehabilitation facility, long-term care facility).

    Time frame: 3 months after hospital discharge.

  10. Living Situation at 6 Months after Discharge

    Living situation of participants at 6 months after hospital discharge

    Time frame: 6 months after hospital discharge.

  11. Demographic Characteristics of Participants

    Baseline demographic characteristics of participants, including age and sex.

    Time frame: Baseline.

  12. Living Situation at Baseline

    Living situation of participants prior to hospital admission.

    Time frame: Baseline.

  13. Prevalence of Comorbidities

    Prevalence of pre-existing comorbidities at baseline.

    Time frame: Baseline.

  14. Vaccination Status

    Proportion of participants vaccinated against influenza, SARS-CoV-2, and respiratory syncytial virus (RSV).

    Time frame: Baseline.

  15. Time since last vaccination

    Time elapsed since the most recent vaccination against influenza, SARS-CoV-2, or RSV, measured in months.

    Time frame: Baseline.

  16. Pneumonia Severity Index (PSI) Score

    Severity of pneumonia assessed using the Pneumonia Severity Index (PSI) score at hospital admission.

    Time frame: Baseline

07

Study locations

3 of 24 sites recruiting
  • University of Rochester School of Medicine, Infectious Diseases Unit
    Rochester, New York 14642, United States
    Recruiting
    • Edward Walsh, MD PhD · Contact
  • University Hospital of Amiens
    Amiens, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Melun Hospital
    Melun, France
    Recruiting
    • Sylvain DIAMANTIS, MD · Contact
  • Villeneuve Saint Georges Hospital
    Paris, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • University Hospital of Poitiers
    Poitiers, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • University Hospital of Reims
    Reims, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • University Hospital of Tours
    Tours, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Klinikum Bayreuth, Klinik für Geriatrie
    Bayreuth, Germany
    Not yet recruiting
    • Hans-Jürgen Heppner, MD PhD · Contact
  • Abteilung Geriatrie Universitätsmedizin Göttingen, Abteilung Geriatrie
    Göttingen, Germany
    Not yet recruiting
    • Christine Von Arnim, MD PhD · Contact
  • Uniklinikum Jena, Klinik für Geriatrie
    Jena, Germany
    Not yet recruiting
    • Kristin Häseler-Ouart, MD · Contact
  • Universitätsmedizin Mannheim, IV. Medizinische Klinik (Geriatrie)
    Mannheim, Germany
    Not yet recruiting
    • Heinrich Burkhardt, MD PhD · Contact
  • Klinikum Ulm, Geriatrisches Zentrum Agaplesion Bethesda
    Ulm, Germany
    Not yet recruiting
    • Michael Denkinger, MD PhD · Contact
  • University of Bari, Bari
    Bari, Italy
    Not yet recruiting
    • Francesco Di Gennaro, MD · Contact
  • Azienda Ospedaliero Universitaria "Renato Dulbecco", Catanzaro
    Catanzaro, Italy
    Not yet recruiting
    • Elvira Bonacci, MD · Contact
  • ULSS 5 Polesana, Rovigo
    Rovigo, Italy
    Not yet recruiting
    • Pierluigi Dal Santo, MD · Contact
  • ASL 1 Imperiese, Sanremo
    Sanremo, Italy
    Not yet recruiting
    • Giovanni Cenderello, MD · Contact
  • Città di Torino, Torino
    Torino, Italy
    Not yet recruiting
    • Antonino Maria Cotroneo, MD · Contact
  • APSS Trento, Geriatria, Trento
    Trento, Italy
    Not yet recruiting
    • Anna Casanova, MD · Contact
  • ASUGI, Trieste
    Trieste, Italy
    Not yet recruiting
    • Michela Zanetti, MD · Contact
  • ULSS 3 Serenissima, Venice
    Venice, Italy
    Not yet recruiting
    • Ernesto Rampin, MD · Contact
  • ULSS 9 Scaligera, Legnago, Verona
    Verona, Italy
    Not yet recruiting
    • Margherita Azzini, MD · Contact
  • Hospital Clínic Barcelona Servicio de Geriatría
    Barcelona, Spain
    Recruiting
    • Juan Manuel Pérez Castejón, MD · Contact
  • Hospital Universitario Ramón y Cajal. Madrid Servicio de Geriatría
    Madrid, Spain
    Not yet recruiting
    • Alfonso J. Cruz Jentoft, MD · Contact
  • Hospital Universitario Virgen de la Arrixaca Murcia Servicio de Geriatría
    Murcia, Spain
    Not yet recruiting
    • Juan Dionisio Avilés Hernández, MD · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Jan 2028, 24 months after the start.

Of 67 non-industry observational studies under Respiratory Tract Infections, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 24 months is close to that.

Counting every sponsor, half of 86 studies reached it within 18 months; a quarter within 8 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 29, 2025
First posted
Feb 4, 2026
StartActual
Jan 15, 2026
Primary completionEst.
Jan 15, 2028
CompletionEst.
Jun 15, 2028
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07388173
Responsible party
Sponsor
First posted
Feb 4, 2026
Start date
Jan 15, 2026
Primary completion
Jan 15, 2028 (estimated)
Completion
Jun 15, 2028 (estimated)
Last update
May 8, 2026

Study contacts

Gaetan GAVAZZI, MD,PhD
Contact
GGavazzi@chu-grenoble.fr
0033(0)476766760
Saber TOUATI, PhD
Contact
stouati1@chu-grenoble.fr
0033(0)476765805

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion